8-K: Biofrontera Inc. Secures $11 Million Investment and Full U.S. Rights to Ameluz and RhodoLED, Paving Path to Profitability

Biofrontera Inc. announced a significant restructuring of its relationship with Biofrontera AG, acquiring all U.S. rights to its key products Ameluz and RhodoLED, backed by an $11 million investment aimed at achieving profitability.

Summary

• Biofrontera Inc. has signed an agreement to acquire all U.S. assets related to Ameluz and RhodoLED, including the New Drug Application (NDA) and associated patents, from Germany-based Biofrontera AG.
• The effective royalty rate paid by Biofrontera Inc. will be reduced to 12% of net sales when U.S. Ameluz revenue is less than $65 million, and 15% when revenue exceeds that threshold, replacing the previous 25% to 35% transfer pricing model.
• An $11 million investment, led by existing investors Rosalind Advisors and AIGH Capital Management LLC, is expected to fund Biofrontera Inc. to profitability.
• Biofrontera AG will receive a 10% post-money equity stake in Biofrontera Inc., aligning long-term interests between the entities.
• Responsibility for the manufacture of Ameluz and the RhodoLED lamp portfolio for the U.S. market, along with all regulatory, quality management, pharmacovigilance, and commercial responsibilities, will transfer entirely to Biofrontera Inc.
• The $11 million investment will be funded in two tranches: $8.5 million upon signing the new royalty agreement, and $2.5 million upon finalization of a detailed asset transfer agreement, which is expected by September 30, 2025.
• The new capital will be provided in the form of preferred shares convertible to common shares at the market price of $0.6249 per share as of the close of business on June 26, 2025.

Sentiment

Score: 8

Explanation: The announcement is highly positive, detailing a strategic acquisition, significant cost reductions through a new royalty structure, and a substantial capital injection, all aimed at achieving profitability and unlocking market potential. The alignment of interests with Biofrontera AG further strengthens the outlook.

Positives

• Acquisition of full U.S. rights to Ameluz and RhodoLED provides Biofrontera Inc. complete control and accountability for product success in the U.S. market.
• Reduced royalty rates from 25-35% to 12-15% are expected to significantly lower costs and accelerate the path to breakeven and future profitability.
• The $11 million investment provides crucial capital to fund operations and the acquisition, supporting the company's growth strategy.
• Biofrontera AG's 10% post-money equity stake aligns the long-term interests of both entities.
• Increased operational agility and ability to drive commercial and operational decisions independently.
• The transaction creates clarity and alignment, which is expected to unlock significant untapped potential for Ameluz in the U.S. market.

Negatives

• The second tranche of $2.5 million is contingent on the finalization of a detailed asset transfer agreement, introducing a minor contingency.

Risks

• Impact of any extraordinary external events.
• Changes in the company's relationship with its business partners.
• The ability of the company's manufacturers to fulfill their obligations to the company in a timely manner.
• The company's ability to achieve and sustain profitability.
• Whether current global disruptions in supply chains will impact the company's ability to obtain and distribute its products.
• Changes in the practices of healthcare providers, including any changes to the coverage, reimbursement, and pricing for procedures using the company's products.
• Uncertainties inherent in the initiation and conduct of clinical trials.
• Availability and timing of data from clinical trials.
• Whether results of earlier clinical trials or trials of Ameluz in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials.
• Uncertainties associated with regulatory review of clinical trials and applications for marketing approvals.
• Whether the market opportunity for Ameluz in combination with BF-RhodoLED and/or RhodoLED XL is consistent with the company's expectations.
• The company's ability to retain and hire key personnel.
• Sufficiency of cash resources and need for additional financing.

Future Outlook

The company expects the restructuring and investment to fund it to profitability and reach breakeven more quickly. It plans an upcoming FDA submission for the treatment of superficial basal cell carcinoma, signaling continued commitment to realizing the potential of photodynamic therapy in dermatology.

Management Comments

• "This acquisition gives us full control and accountability for the success of Ameluz and RhodoLED in the U.S. It allows us to drive commercial and operational decisions with greater agility. The move from transfer pricing to a royalty-based agreement and the resulting cost reductions will allow us to reach breakeven more quickly and be more profitable in the future. This agreement, coupled with our upcoming FDA submission for the treatment of superficial basal cell carcinoma, signals our continued commitment to realizing the potential of PDT in dermatology." Dr. Hermann Luebbert, President and CEO of Biofrontera Inc.
• "Ameluz has significant untapped potential in the U.S. market. This transformational announcement creates the clarity and alignment needed to unlock that value. We are excited to support Biofrontera Inc. through its next phase of growth." Dr. Gil Aharon of Rosalind Advisors Inc.

Industry Context

This announcement positions Biofrontera Inc. to strengthen its presence in the U.S. dermatology market, specifically within the photodynamic therapy (PDT) segment. By gaining full control over Ameluz and RhodoLED, the company can more effectively compete and expand its market share for treating actinic keratosis and potentially non-melanoma skin cancers and moderate to severe acne, aligning with broader trends of specialized dermatological treatments.

Related Party Transactions

• Biofrontera Inc. has signed an agreement to restructure its relationship with Biofrontera AG, its former parent company.
• This includes the acquisition of all U.S. assets related to Ameluz and RhodoLED from Biofrontera AG.
• Biofrontera AG will receive a 10% post-money equity stake in Biofrontera Inc. as part of the agreement.

Stakeholder Impact

• Shareholders: Expected to benefit from improved financial performance, accelerated path to profitability, and unlocking of market potential due to reduced costs and increased operational control. The $11 million investment provides financial stability.
• Employees: Increased control over U.S. operations may lead to more focused strategic direction and potentially new opportunities within Biofrontera Inc. as responsibilities transfer from Biofrontera AG.
• Customers (Healthcare Providers/Patients): Potential for more agile commercial and operational decisions regarding Ameluz and RhodoLED in the U.S. market, potentially leading to better product availability or support.
• Creditors: Improved financial outlook and capital injection could enhance the company's creditworthiness.
• Suppliers: Transfer of manufacturing responsibility to Biofrontera Inc. could impact existing supplier relationships or create new ones.

Next Steps

• Finalization of a detailed asset transfer agreement, expected by September 30, 2025.
• Upcoming FDA submission for the treatment of superficial basal cell carcinoma.
• Continued efforts to realize the potential of photodynamic therapy in dermatology.

Key Dates

Recommendation

Keywords

Biofrontera Inc., BFRI, Biofrontera AG, Ameluz, RhodoLED, photodynamic therapy, PDT, actinic keratosis, superficial basal cell carcinoma, dermatology, biopharmaceutical, corporate restructuring, investment, royalty agreement, asset acquisition, FDA submission, Rosalind Advisors, AIGH Capital Management